Kc Cheng

KC Cheng is an experienced professional with a comprehensive background in analytical and formulation development within the biopharmaceutical industry. Currently serving as Executive Director at Incyte since June 2019, KC Cheng has been responsible for developing strategies for analytical packages supporting clinical studies and reviewing regulatory filings. Previous roles include Senior Director at VPP/VRC/NIAID/NIH, where KC Cheng managed assay development and IND filings, and Senior Director at Actinium Pharmaceuticals, focusing on quality assurance and CMC filings for biological drug production. Additional experience includes leadership positions at Bristol-Myers Squibb, Medarex, and Ortho Biotech, with significant contributions to drug development across various phases. KC Cheng holds an Executive MBA in Finance from Rutgers University and a PhD in Biochemistry from the University of Notre Dame.